arrow
M

Meiting Chen

Chinese Academy of Sciences
H指数:18
被引数:1,407

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Germline Pathogenic Variants in HER2-Positive Breast Cancer: Spectrum and Clinical Implications in a High-Risk Chinese Cohort

HER2阳性乳腺癌中的胚系致病性变异:高风险中国队列中的谱系及临床意义

2026-05-150
OAAI
Tumor microenvironment-responsive nanoparticles composed of hyaluronic acid and stearic acid for the treatment of lung metastasis in triple-negative breast cancer

由透明质酸和硬脂酸组成的肿瘤微环境响应性纳米粒,用于治疗三阴性乳腺癌的肺转移

2025-12-120
PRE
Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study

未分化原发性癌症的免疫检查点抑制剂为基础疗法的临床结果与基因组生物标志物:一项多中心、真实世界研究

2025-07-120
OA
Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study): A phase III crossover trial

奥氮平联合标准止吐药预防接受5天顺铂为基础化疗的生殖细胞瘤患者恶心呕吐(NAVIGATE研究):一项III期交叉试验

2025-06-010
PRE
De novo designed mini-binders targeting glyceraldehyde-3-phosphate dehydrogenase of Streptococcus equi ssp. zooepidemicus provided partial protection in mice model of infection

从头设计的靶向马链球菌 zooepidemicus 亚种甘油醛-3-磷酸脱氢酶的 mini-binders 在感染小鼠模型中提供了部分保护。

2025-05-010
PRE
RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study

RC48-ADC单药治疗或联合免疫疗法治疗HER2低表达和零表达的局部晚期或转移性尿路上皮癌:一项多中心、真实世界、回顾性研究

2025-04-300
OA
Mini-binders targeting Streptococcus equi ssp. zooepidemicus M-like protein inhibit the bacterial adhesion and exert protective effects in vivo

靶向Streptococcus equi ssp. zooepidemicus M-like protein的迷你结合剂可抑制细菌粘附并在体内发挥保护作用

2025-04-011
PRE
PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First-Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study

PD-1/PD-L1抑制剂联合化疗与单用化疗作为不明原因原发灶不良癌症患者的一线治疗方案:一项多中心、回顾性队列研究

MEDCOMM
IF10.7
2025-03-060
OAAI